Considering the novelty of this study, while TP53, ATM, and RAD51 have been individually implicated in radiotherapy resistance, our study presents a novel integrative approach by identifying and functionally validating the combined regulatory impact of TP53, RAD51, and BAX in gastric cancer, with supporting evidence for ATM’s epigenetic suppression. This evidence concerns the gene TP53 and gastric cancer.